Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
5.600
-0.030 (-0.53%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stocks That Hit 52-Week Lows On Friday
December 30, 2022
Friday's session saw 75 companies set new 52-week lows.
Via
Benzinga
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
December 19, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
December 08, 2022
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
November 01, 2022
Via
Benzinga
Analyst Initiates Coverage On This Genetic Testing Stock With Ongoing Transformation
October 06, 2022
Via
Benzinga
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
November 29, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
November 17, 2022
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
November 14, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
November 10, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why Shares of Myriad Genetics Dropped 24% This Week
November 03, 2022
The genetic-testing company announced an acquisition and lowered its guidance.
Via
The Motley Fool
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
November 03, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
November 02, 2022
Gainers
Via
Benzinga
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
November 01, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 01, 2022
Gainers
Via
Benzinga
Dow Drops Over 200 Points; Crude Oil Rises Sharply
November 01, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Tuesday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 01, 2022
On Tuesday, 85 stocks hit new 52-week lows.
Via
Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
November 01, 2022
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads.
Via
Benzinga
Goodyear Tire, Catalent, Zebra Technologies And Some Other Big Stocks Moving Lower On Tuesday
November 01, 2022
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Myriad Genetics: Q3 Earnings Insights
November 01, 2022
Myriad Genetics (NASDAQ:MYGN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 09:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
November 01, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Third Quarter Financial Results
November 01, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
October 31, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 1, 2022
November 01, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
Via
Benzinga
Earnings Preview: Myriad Genetics
October 31, 2022
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that Myriad...
Via
Benzinga
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
October 26, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Precision Medicine Could Get Even More Precise With Allarity Therapeutics' "Next-Generation" Diagnostics Platform
October 17, 2022
Allarity Therapeutics Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on oncology treatments.
Via
Benzinga
Is Illumina Still the Gamechanger in Genomics Sequencing?
October 04, 2022
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Via
MarketBeat
Topics
Earnings
Economy
Lawsuit
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
October 06, 2022
Upgrades
Via
Benzinga
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
September 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022
July 28, 2022
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.